Ascendis Pharma A/S (ASND) Financial Statements
Ascendis Pharma A/S financial statements at a glance
Ascendis Pharma A/S reported revenue of 720.13 million EUR for fiscal year 2025 (ended December 31, 2025), up 98.0% from fiscal year 2024. Net income was -228.03 million EUR, a net margin of 31.7% loss, and diluted earnings per share were -3.76 EUR.
At the end of fiscal year 2025 it had total assets of 1.30 billion EUR, total liabilities of 1.47 billion EUR and shareholders' equity of -162.82 million EUR, with cash and short-term investments of 616.04 million EUR and total debt of 871.79 million EUR.
Its operations brought in 53.90 million EUR of cash; capital spending was 8.49 million EUR, leaving free cash flow of 45.41 million EUR.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.
Figures from company filings, in EUR; latest fiscal year ended December 31, 2025.
Ascendis Pharma A/S
Income Statement
Annual • EUR
Ascendis Pharma A/S key figures by fiscal year
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | 720.1M EUR | 363.6M EUR | 266.7M EUR | 51.2M EUR | 7.8M EUR |
| Gross profit | 625.2M EUR | 319.4M EUR | 222.3M EUR | 39.0M EUR | 4.3M EUR |
| Operating income | -136.3M EUR | -278.8M EUR | -455.5M EUR | -561.8M EUR | -451.8M EUR |
| Net income | -228.0M EUR | -378.1M EUR | -481.4M EUR | -583.2M EUR | -383.6M EUR |
| Diluted EPS | -3.76 EUR | -6.53 EUR | -8.55 EUR | -10.40 EUR | -7.00 EUR |
| Total assets | 1.3B EUR | 1.2B EUR | 825.6M EUR | 1.1B EUR | 1.1B EUR |
| Total liabilities | 1.5B EUR | 1.3B EUR | 971.3M EUR | 826.4M EUR | 201.3M EUR |
| Shareholders' equity | -162.8M EUR | -105.7M EUR | -145.7M EUR | 263.3M EUR | 883.6M EUR |
| Cash and short-term investments | 616.0M EUR | 559.5M EUR | 399.4M EUR | 735.5M EUR | 682.1M EUR |
| Total debt | 871.8M EUR | 856.6M EUR | 644.3M EUR | 508.4M EUR | 105.0M EUR |
| Operating cash flow | 53.9M EUR | -306.2M EUR | -467.4M EUR | -495.7M EUR | -417.6M EUR |
| Capital spending | 8.5M EUR | 1.4M EUR | 2.4M EUR | 14.5M EUR | 24.2M EUR |
| Free cash flow | 45.4M EUR | -307.6M EUR | -469.8M EUR | -510.2M EUR | -441.9M EUR |
In EUR. Fiscal years as reported by the company; statements on this page go back to fiscal year 2020.
Questions and answers
What was Ascendis Pharma A/S's revenue in fiscal year 2025?
720.13 million EUR, up 98.0% from 363.64 million EUR in fiscal year 2024.
How much profit does Ascendis Pharma A/S make?
Ascendis Pharma A/S reported net income of -228.03 million EUR for fiscal year 2025 (31.7% of revenue); operating income was -136.27 million EUR.
How much cash and debt does Ascendis Pharma A/S have?
At the end of fiscal year 2025: cash and short-term investments of 616.04 million EUR and total debt of 871.79 million EUR.
What is Ascendis Pharma A/S's free cash flow?
45.41 million EUR in fiscal year 2025 (operating cash flow of 53.90 million EUR minus capital spending of 8.49 million EUR).
